Advocacy intelligence hub — real-time data for patient organizations
Baylor College of Medicine — PHASE1
Fred Hutchinson Cancer Center — PHASE1, PHASE2
Fudan University
Ruijin Hospital
Evopoint Biosciences Inc. — PHASE3
Peking University Cancer Hospital & Institute — PHASE1, PHASE2
Zhejiang University — EARLY_PHASE1
Institute of Hematology & Blood Diseases Hospital, China — PHASE1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Bexxar
GlaxoSmithKline LLC
Patient Assistance Programs1
Rituxan
Genentech, Inc.
Istodax
(romidepsin)Orphan drugCelgene Corporation
12.1 Mechanism of Action Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine resi...
Zolinza
(vorinostat)Orphan drugMerck & Co., Inc.
Histone Deacetylase Inhibitor [EPC]
12.1 Mechanism of Action Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at n...
Bexxar
(Tositumomab and iodine I 131 tositumomab)Orphan drugGlaxoSmithKline LLC
He Huang, MD
Zhejiang University
📍 Hanzhou, Zhejiang
Pier Luigi Zinzani, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Central Contact
Astellas Pharma Global Development
Nirav Shah, MD
Medical College of Wisconsin
Lawrence Kaplan, MD
University of California, San Francisco
Yuqin Song
Cancer Hospital of Beijing University